RXST logo

RxSight Inc. (RXST)

$8.85

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RXST

Market cap

$363882264

EPS

-0.87

P/E ratio

--

Price to sales

2.5

Dividend yield

--

Beta

1.130633

Price on RXST

Previous close

$8.63

Today's open

$8.66

Day's range

$8.57 - $8.86

52 week range

$6.32 - $29.79

Profile about RXST

CEO

Ron Kurtz

Employees

498

Headquarters

Aliso Viejo, CA

Exchange

NASDAQ Global Market

Shares outstanding

41116640

Issue type

Common Stock

RXST industries and sectors

Healthcare

Medical Equipment & Supplies

News on RXST

Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Feb 18, 2026

news preview

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

news source

GlobeNewsWire • Feb 11, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext.

news source

PRNewsWire • Jan 22, 2026

news preview

RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

news source

Seeking Alpha • Jan 14, 2026

news preview

RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock?

RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

news source

Zacks Investment Research • Jan 13, 2026

news preview

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition.

news source

GlobeNewsWire • Jan 11, 2026

news preview

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

news source

GlobeNewsWire • Jan 2, 2026

news preview

RxSight, Inc. Announces Chief Financial Officer Transition

ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company's Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.

news source

GlobeNewsWire • Dec 22, 2025

news preview

RxSight, Inc. to Present at the Piper Sandler Healthcare Conference

ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City.

news source

GlobeNewsWire • Nov 20, 2025

news preview

RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript

RxSight, Inc. ( RXST ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Oliver Moravcevic Ronald Kurtz - Co-President, CEO & Director Shelley Thunen - Co-President & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division David Saxon - Needham & Company, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Patrick Wood - Morgan Stanley, Research Division K. Gong - JPMorgan Chase & Co, Research Division Adam Maeder - Piper Sandler & Co., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, everyone.

news source

Seeking Alpha • Nov 6, 2025

news preview

¹ Disclosures

Get started with M1

Invest in RxSight Inc.

Open an M1 investment account to buy and sell RxSight Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RXST on M1